EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Current Evidence and Future Directions of PCSK9 Inhibition

Jiaqian Xu, Michael D Shapiro

US Cardiology Review · 16.02.2021 · 15

DOI: 10.15420/usc.2020.17 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift US Cardiology Review, online erschienen am 16.02.2021. Verfasst von Jiaqian Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University Baptist Medical Center Winston Salem,…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent scientific and therapeutic advances in proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition have opened a chapter in the management of hypercholesterolemia, especially in patients who are inadequately controlled on or intolerant to statins. The two PCSK9 monoclonal antibodies, evolocumab and alirocumab, reduce LDL cholesterol by 60% and improve cardiovascular outcomes when taken in addition to statin therapy. More recently, inclisiran, a silencing RNA (siRNA) that inhibits translation of PCSK9 mRNA, demonstrated LDL cholesterol reduction by 45–50% with the advantage of dramatically reduced dose frequency. Other modes of PCSK9 inhibition include small molecule antagonists, vaccines, CRISPR gene editing, and antagonism at various steps of translation, and post-translational processing.

Schlagwörter

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseLDL cholesterolhypercholesterolemiaproprotein convertase subtilisin/kexin type 9silencing RNA

Autor:innen und Institutionen

  • Center for the Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University Baptist Medical Center Winston Salem, NC.

Zitieren

APA

Xu, J., & Shapiro, M. D. (2021). Current Evidence and Future Directions of PCSK9 Inhibition. US Cardiology Review, 15. https://doi.org/10.15420/usc.2020.17

Vancouver

Xu J, Shapiro MD. Current Evidence and Future Directions of PCSK9 Inhibition. US Cardiology Review. 2021;15. doi:10.15420/usc.2020.17

BibTeX
@article{Xu2021,
  author = {Xu, Jiaqian and Shapiro, Michael D},
  title = {Current Evidence and Future Directions of PCSK9 Inhibition},
  journal = {US Cardiology Review},
  year = {2021},
  volume = {15},
  doi = {10.15420/usc.2020.17}
}
Kostenlos starten →